Get the Stockscreener App
48.46
0.59%
-0.29
Supernus Pharmaceuticals Inc stock is traded at $48.46, with a volume of 1.13M.
It is down -0.59% in the last 24 hours and up +7.47% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
See More
Previous Close:
$48.75
Open:
$48.8
24h Volume:
1.13M
Relative Volume:
1.52
Market Cap:
$2.81B
Revenue:
$776.83M
Net Income/Loss:
$-29.02M
P/E Ratio:
-94.65
EPS:
-0.512
Net Cash Flow:
$82.25M
1W Performance:
+0.85%
1M Performance:
+7.47%
6M Performance:
-5.18%
1Y Performance:
+46.23%
1-Day Range:
$47.39
$48.80
1-Week Range:
$46.76
$51.37
52-Week Range:
$32.20
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
48.46 | 2.81B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Avoiding Lag: Real-Time Signals in (SUPN) Movement - Stock Traders Daily
SUPN Maintained by Cantor Fitzgerald -- Price Target Raised to $67.00 - GuruFocus
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength? - Yahoo Finance UK
Britannia, US WorldMeds, Supernus move for judgment in US antitrust case on Apokyn - MLex
Jack Khattar: Innovator, Business Leader, and Founder, President and CEO of Supernus Pharmaceuticals - BBN Times
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – BX:S49 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – DUS:S49 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals (SUPN) Following Shelf Filing Has Its Undervalued Case In Focus - Sahm
Price to sales forward of Supernus Pharmaceuticals, Inc. – FWB:S49 - TradingView
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
SUPN Q1 2026 Earnings: EPS Surges 97.69% Above EstimatesEarnings Sentiment Score - dars.gov.et
Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Q3 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49) - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSE:0LB2) - TradingView
S49 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
SUPN Forecast — Price Target — Prediction for 2027 - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSX:A1JX3U) - TradingView
0LB2 Forecast — Price Target — Prediction for 2027 - TradingView
A1JX3U Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Enterprise value to revenue forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals Insiders Sold US$2.1m Of Shares Suggesting Hesitancy - 富途牛牛
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest - Yahoo Finance
How Strong Quarterly Results and MERGE Partnership Will Impact Supernus Pharmaceuticals (SUPN) Investors - Sahm
Supernus Investors Approve Directors, Pay and Incentive Plan - The Globe and Mail
Supernus Pharmaceuticals shareholders approve director elections and key proposals - Investing.com UK
Supernus Pharmaceuticals shareholders approve director elections and key proposals By Investing.com - Investing.com Nigeria
Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan - Stock Titan
Behavioral Patterns of SUPN and Institutional Flows - Stock Traders Daily
Supernus Pharmaceuticals Inc (SUPN) Institutional Confidence - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Inc (SUPN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record - Investing.com
Supernus Pharmaceuticals Inc - TradingKey
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record - The Manila Times
Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Supernus Pharmaceuticals (SUPN) Holds Steady at Key Support: Consolidation Phase Ahead?Wave Extension - dars.gov.et
Supernus Pharmaceuticals Inc (SUPN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
3.42%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):